This company listing is no longer active
6XA Stock Overview
Develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 6XA from our risk checks.
Olink Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.00 |
| 52 Week High | US$24.00 |
| 52 Week Low | US$13.10 |
| Beta | 0.52 |
| 11 Month Change | 4.35% |
| 3 Month Change | 12.15% |
| 1 Year Change | 42.01% |
| 33 Year Change | -17.81% |
| 5 Year Change | n/a |
| Change since IPO | -6.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6XA | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0.8% | -0.2% | 1.5% |
| 1Y | 42.0% | 3.5% | 12.6% |
Return vs Industry: 6XA exceeded the German Life Sciences industry which returned -12.7% over the past year.
Return vs Market: 6XA exceeded the German Market which returned 2.9% over the past year.
Price Volatility
| 6XA volatility | |
|---|---|
| 6XA Average Weekly Movement | 2.2% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6XA has not had significant price volatility in the past 3 months.
Volatility Over Time: 6XA's weekly volatility has decreased from 9% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 707 | Jon Heimer | www.olink.com |
Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company’s products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. Its products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and data analysis and bioinformatics services.
Olink Holding AB (publ) Fundamentals Summary
| 6XA fundamental statistics | |
|---|---|
| Market cap | €3.00b |
| Earnings (TTM) | -€31.07m |
| Revenue (TTM) | €157.54m |
19.0x
P/S Ratio-96.5x
P/E RatioIs 6XA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6XA income statement (TTM) | |
|---|---|
| Revenue | US$170.89m |
| Cost of Revenue | US$56.60m |
| Gross Profit | US$114.29m |
| Other Expenses | US$148.00m |
| Earnings | -US$33.70m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 66.88% |
| Net Profit Margin | -19.72% |
| Debt/Equity Ratio | 0% |
How did 6XA perform over the long term?
See historical performance and comparison